In conclusion, inhibiting the B7-1/CD28 signaling pathway is able to alleviate experimental lupus nephritis and provides an experimental basis for the therapeutic use of blocking the B7-1/CD28 signaling pathway in human lupus nephritis and other autoimmune disorders. Here, CD80 is linked to autoimmune disease.